A Retrospective Comparison of Phaco-Tube vs. Phaco-Trabeculectomy in Glaucoma Patients

Cristina N Llaneras; Ann Quan; Caroline Lieux; Erick Rivera-Grana; Consuelo Gajardo; Eric Duerr; Robert C O'Brien; Steven J Gedde; Luis E Vazquez

doi:10.1016/j.ogla.2024.04.008

A Retrospective Comparison of Phaco-Tube vs. Phaco-Trabeculectomy in Glaucoma Patients

Ophthalmol Glaucoma. 2024 Apr 30:S2589-4196(24)00072-3. doi: 10.1016/j.ogla.2024.04.008. Online ahead of print.

Authors

Cristina N Llaneras¹, Ann Quan², Caroline Lieux¹, Erick Rivera-Grana¹, Consuelo Gajardo¹, Eric Duerr¹, Robert C O'Brien¹, Steven J Gedde¹, Luis E Vazquez³

Affiliations

¹ Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
² Division of Ophthalmology, Scripps Clinic, La Jolla, California, USA.
³ Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: LVazquez@med.miami.edu.

PMID: 38697359
DOI: 10.1016/j.ogla.2024.04.008

Abstract

Purpose: To compare surgical outcomes of phacoemulsification combined with Baerveldt implantation (phaco-tube) or trabeculectomy with mitomycin-C (MMC) (phaco-trab) in patients without prior incisional ocular surgery.

Design: Single-center, retrospective, comparative case series.

Participants: A total of 90 patients underwent surgical treatment, including 45 patients in the phaco-tube group and 45 patients in the phaco-trab group.

Methods: Eligible patients were identified using current procedural terminology (CPT) codes, and their medical records were retrospectively reviewed.

Main outcome measures: The primary outcome measure was the rate of surgical failure (IOP ≤5 mmHg or >21 mmHg or reduced <20% from baseline on two consecutive study visits after 3 months, reoperations for glaucoma, or experienced loss of light perception vision). Patients who had successful surgical outcomes without use of glaucoma medications were classified as complete successes, while those that used glaucoma medications were classified as qualified successes. Secondary outcome measures were visual acuity (VA), visual field mean deviation (VFMD), intraocular pressure (IOP), glaucoma medication use, and complications.

Results: The cumulative probability of failure was 6.7% in the phaco-tube group and 32.8% in the phaco-trab group after 3 years (P= 0.005; Restricted Mean Survival Time = 5.9 months, 95% CI = 1.4 to 10.4 months). IOP was 13.1 ± 3.4 mmHg in the phaco-tube group and 13.3 ± 6.2 mmHg in the phaco-trab group at 3 years (P= 0.90), and the number of glaucoma medications was 2.6 ± 1.5 in the phaco-tube group and 1.7 ± 1.3 in the phaco-trab group (P= 0.015). LogMAR VA was 0.39 ± 0.58 in the phaco-tube group and 0.43 ± 0.73 in the phaco-trab group at 3 years (P= 0.82) and VFMD was -18.3 ± 9.0 dB in the phaco-tube group and -14.1 ± 7.0 dB in the phaco-trab group (P= 0.16). Postoperative complications developed in 21 patients (47%) in the phaco-tube group and 15 patients (33%) in the phaco-trab group (P= 0.28).

Conclusions: Phaco-tubes had a significantly lower rate of surgical failure compared to phaco-trabs after 3 years of follow-up. However, phaco-trabs used significantly fewer glaucoma medications at multiple postoperative timepoints and had a higher proportion of complete success.

Keywords: Glaucoma Surgery; Phacoemulsification; Trabeculectomy; Tube Shunt.